Table 2.
Selected clinical trials using lenalidomide in combination for treatment CLL. NR: not reported.
| Study | Regimen | No. of patients | TLS all grades | TFR all grades | Hematologic side effects grade 3/4 | OR (%) | CR (%) | OS (%) | PFS |
|---|---|---|---|---|---|---|---|---|---|
| Ferrajoli et al. [22] phase II relapsed/refractory CLL |
10 mg/d Lenalidomide + rituximab weekly | 59 | 1,7% | 37% | Neutropenia 68% thrombocytopenia 22% anemia 10% | 64 | 8 | NR | NR |
|
| |||||||||
| Badoux et al. [24] phase II relapsed/refractory CLL |
10 mg/d lenalidomide + ofatumumab weekly | 16 | NR | 13% | Neutropenia 50% anemia 13% |
63 | 13 | NR | NR |
|
| |||||||||
| Blum et al. [29] phase I relapsed/refractory CLL |
2.5 mg/d escalated to 25 mg/d lenalidomide + flavopiridol | 15 | 14% | 7% | Neutropenia 86% thrombocytopenia 38% anemia 38% | 46 | 0 | NR | NR |
|
| |||||||||
| GIMEMA LLC 606 [25] phase I relapsed/refractory CLL |
2.5 mg/d escalated to 15 mg/d lenalidomide + cyclophosphamide + fludarabine | 9 | 0 | 11% | Transient grade 3-4 neutropenia in the majority of pts | 67 | 33 | NR | NR |
|
| |||||||||
| Egle et al. [27] phase untreated CLL |
2.5 mg/d escalated to 25 mg/d lenalidomide + fludarabine + rituximab | 10 | 0 | 0 | Neutropenia 70% | 90 | 0 | NR | NR |